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Abstract.  During blood clot formation in vivo, plasma 
fibronectin (pFN) is cross-linked to fibrin by coagula- 
tion factor XIIIa.  Cellular FN (cFN), which localizes 
to connective tissue, is distinguished  from pFN by the 
inclusion of alternatively spliced segments.  To deter- 
mine if these two FNs are functionally equivalent in 
blood clotting, the cross-linking of rat pFN and cFN 
to fibrin was compared in an in vitro clotting assay. 
Fibrinogen and FN were incubated at physiological ra- 
tios in the presence of thrombin and factor Xl]Ia. 
Cross-linking  of FN to fibrin was monitored by SDS- 
PAGE and immunoblotting.  Over 24 h,  cFN was in- 
corporated at a  significantly slower rate than pFN and 
was not completely cross-linked to fibrin at a tempera- 
ture that favors this interaction  (0~  This difference 
was observed with purified fibrinogens from human, 
rat,  and bovine and with rat plasma and was main- 
tained even after incubation of pFN with rat fibro- 
blasts for several days. Using the same assay,  purified 
recombinant V+-V0 and V+-V  + FN dimers resembling 
pFN and cFN, respectively, showed a  similar differ- 
ence in cross-linking kinetics.  These results suggest 
that the asymmetric distribution of the V region among 
pFN dimers plays a role in regulating its incorporation 
into blood clots. 
In fibrin clots, cFN was converted into a set of cross- 
linked intermediates distinct from those of pFN.  For 
example, while pFN was initially cross-linked into a 
pFN-fibrin ct heterodimer,  this product was not a ma- 
jor intermediate in clots formed with cFN.  This find- 
ing,  in conjunction with evidence for the formation of 
factor XIIIa-catalyzed cFN-cFN cross-links,  indicated 
that cFN molecules interact with each other,  and with 
fibrin, differently from pFN.  Together,  these results 
show an important functional distinction between pFN 
and cFN. 
I 
n  tissue repair and remodeling,  fibronectin  (FN) ~  plays 
a crucial role in the assembly of specialized  matrices 
important for these processes. When blood vessel injury 
occurs in an incisional  skin wound, for example, leakage of 
plasma proteins into extravascular  spaces activates  zymo- 
gens of the clotting  cascade to form a bemostatic plug,  or 
blood clot (see Furie and Furie,  1988),  containing  fibrin, 
erythrocytes, platelets,  and plasma FN (pFN) as major com- 
ponents.  This structure is stabilized  by covalent cross-links 
introduced between fibrin molecules (Lorand, 1972) and be- 
tween fibrin and FN molecules by coagulation  factor XlIIa 
(plasma transglutaminase)  (Mosher,  1975, 1976). The fibrin- 
FN clot is adhesive and serves as a provisional  matrix sup- 
porting the migration  of epidermal cells during  wound clo- 
sure and the influx of inflammatory cells, fibroblasts,  and 
endothelial  cells into the wound bed as healing  progresses 
(for reviews,  see Clark and Henson,  1988; Mosher,  1989; 
Hynes, 1990). 
1.  Abbreviations  used  in  this paper:  cFN,  pFN,  and recFN,  cellular, 
plasma, and recombinant fibroneetin,  respectively. 
In its genesis, a blood clot contacts interstitial tissue com- 
posed of collagens,  proteoglycans,  and cellular FN (cFN). 
Fibroblasts migrate from the stroma into the wound (Clark 
and Henson, 1988) to synthesize, secrete, and organize cFN 
into insoluble fibrils, providing a framework for subsequent 
collagen deposition (McDonald et al.,  1982). While fibro- 
blasts and most other cell types, including  endothelial  cells 
and macrophages,  are sources ofcFN, pFN is produced only 
in the liver (see Hynes,  1990).  Although  both forms are 
generated from a single gene, they are structurally differen- 
tiated by cell type-specific alternative  splicing at three sites 
in the FN mRNA, namely, EIIIA, EIIIB, and the V (or vari- 
able) region (for review see Mosher,  1989; Hynes, 1990). 
In the rat, the pattern of splicing in the liver gives rise to pFN 
dimers of characteristic  subunit  composition: one subunit 
has the V region, the other lacks this segment (Schwarzbauer 
et al.,  1989). In contrast, almost all cFN subunits  are V +. 
In addition,  the two extra domains,  EIIIA and EIIIB,  are 
present in a small percentage of cFN subunits but are always 
excluded from pFN dimers (Paul et al., 1986; Schwarzbauer 
et  al.,  1987).  Thus,  differential  splicing  confers  greater 
structural  heterogeneity and complexity to cFN molecules 
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vivo localization, cFN is found as a fibrillar network within 
the tissue extracellular matrix, pFN, the more soluble form, 
circulates  in the blood until  immobilized  by binding  and 
cross-linking  to fibrin during clot formation. 
cFN is an integral component of the wound healing pro- 
cess, where it is present in the surrounding tissue and synthe- 
sized by cells that migrate into the wound area (Clark and 
Henson, 1988). However, it is not known whether cFN par- 
ticipates in one of  the earliest stages of tissue repair, namely, 
cross-linking to fibrin. In this report, we have characterized 
the role of cFN during clot formation in vitro, both by com- 
paring the native rat polypeptide  with pFN, and by com- 
paring cDNA-encoded recombinant dimers that differed in 
V-region complement. When cross-linked clots composed of 
purified  fibrinogen and FNs were analyzed by solubiliza- 
tion, SDS-PAGE, and immunoblotting,  we found that the 
rate of incorporation of cFN, as well as recombinant V+-V  + 
dimers, was significantly slower than that of pFN and its 
corresponding  V+-V0 dimers.  In  addition,  factor  XIIIa- 
mediated  cross-linking between cFN, but not pFN, mole- 
cules  could be detected  in the absence of fibrinogen.  To- 
gether, these results demonstrate that structural differences 
between  pFN and cFN affect their interactions  with each 
other and with fibrin during clot formation. 
Materials and Methods 
Formation of  Fibrin Clots 
Lyophilized  human fibrinogen (98.8%  clonable; American Diagnostica, 
Inc., Greenwich, CT) and bovine fibrinogen (96% clottable; Sigma Chemi- 
cai Co., St. Louis, MO) were reconstituted in buffer to yield stock solutions 
of 6 mg/ml in 0.15 M NaC1 and 10 mM Tris-HCl, pH 7.4. Reconstituted 
fibrinogens were either prepared fresh before an experiment or stored at 
-85~  to retain the activity potential of indigenous factor XHI.  Bovine 
thrombin (Sigma Chemical Co.) was reconstituted with water to ,~0.15 U/#I 
(in 37.5 mM NaC1, 1.25 mM Na citrate, pH 6.5) and stored in 100-/~l ali- 
quots at -20~  At human fibrinogen concentrations ranging from 0.6 to 
3.0 mg/rrd, the factor XlIIa activity was sufficient for the conversion  of fibrin 
-y chains into cross-linked dimers within an hour at 0~  as assessed by 
SDS-PAGE (see Mosher, 1975). Cross-linking of the ot subunits proceeded 
more slowly, as expected; these were not completely incorporated except 
in reactions incubated overnight at this temperature. However, ct polymers 
were detectable within 15-30 rain after the addition of thrombin. 
To maintain the physiological  10:1 mass ratio of fibrinogen  to pFN, clot- 
ting components were mixed in a volume of 50-100/~l to give the following 
concentrations: fibrinogen, 0.6-0.8  mg/ml; pFN or cFN,  60-80 #g/ml; 
thrombin, 1.5 U/nil; 20 mM CaCl2 or EGTA, 0.15 M NaCl, 50 mM Tris- 
HCI,  pH  •7.5.  The concentration of fibrinogen in these reactions was 
fivefold lower than physiological,  but in control experiments, the rates of 
fibrin-FN cross-linking were the same at 0.6 and 3.0 mg/ml. Reaction condi- 
tions were identical for recombinant  FNs (recFNs), except the total FN con- 
centration in each clot,  including recFNs and endogenous SVT2 cFN, 
ranged from 2 to 10/zg/rni, as estimated by band intensities  on silver-stained 
SDS gels. To determine if  this variability had any effect on the rate of cross- 
linking to fibrin, fibrin-FN cross-linking was compared between clots pre- 
pared at 100:1 and 10:1 mass ratios of fibrinogen  to FN. Increasing the ratio 
by an order of magnitude did not change the rate of FN incorporation. 
In some reactions, human placental factor XIII (Calbiochem-Behring 
Corp., San Diego, CA), reconstituted from lyophilized powder to 10 U/nil 
(in 0.5%  serum albumin, 22 mg/ml glycine,  7.2 mg/ml phosphate), was 
added to a final concentration of 1 U/nil (1 U of factor XIII is defined as 
the activity present in 1 ml of plasma). Before the addition of thrombin, the 
mixtures were equilibrated on ice for ;~5 rain. Clots were solubilized  by 
adding an equal volume of S buffer (8 M urea, 2% SDS, 2% 2-mercapto- 
ethanol, 0.16 M Tris-HCI,  pH 6.8), and boiling for 10 rain. 
Freshly prepared rat plasma was passed over a gelatin-agarose column 
to remove endogenous pFN. Plasma clots were prepared essentially  as de- 
scribed above except pFN-depleted plasma represented 30%  of  the reaction 
volume. These conditions gave a fibrinogen concentration of ~0.8 mg/ml, 
equivalent to the concentration used in the fibrin clot assays. 
Construction of  cDNA Encoding recVO 
The construction of the pLJ-recV  + plasmid was outlined previously,  but 
under the designation II-9/C110 (Schwarzbauer,  199t). recV  + in the vector 
pGEP-His (Schwarzbauer et al., 1989) was used to construct the recV0 plas- 
mid. Sequences flanking and including the V region (residues 5536-6765) 
were removed by BstEII (New England Biolabs, Beverly, MA) cleavage and 
replaced with a BstEII fragment encoding the V0 variant.  The absence of 
the 360 nucleotides  that encode the V segment was verified by restriction 
analysis. 
Cell Culture 
G418-resistant SVT2 (SV-40-transformed 3T3) mouse fibroblasts express- 
ing recV  + were generated and grown as described previously  (Schwarz- 
bauer,  1991). For coexpression of recV  + and recV0 polypeptides,  these 
cells were infected with a r  recombinant retrovirus carrying the 
bacterial hisD gene (Hartman and Mulligan, 1988) and sequences encoding 
recV0. Infected cells were selected with 3-4 mM histidinol buffered with 
0.1 M Hepes,  pH 7.3. Resulting colonies were ring cloned, expanded,  and 
screened for expression of both recFNs as described before (Schwarzbauer 
et al., 1989). The F'2408 Rat-1 cell line was cultured in DME supplemented 
with 5 % calf serum (Hyclone Laboratories, Inc., Logan, LIT). Hybridoma 
cells secreting the rat-specific anti-FN mAb VT1 were generously provided 
by Dr.  K.  Fukoda (University of Vermont, Budingtou, VT),  and were 
grown in DME plus 15% FBS. All cells were incubated at 370C in a hu- 
midified atmosphere of 5 % CO2. 
Purification and Cross-linking of  pFN and cFN 
FN was purified from freshly drawn rat plasma, outdated human plasma, 
and the conditioned medium of a Rat-1 F2408 cell line by getatin-agarose 
(Sigma Chemical Co.) chromatography (Engvall  and Ruoslahti,  1977). 
Concentration of FNs was determined by optical density at 280 nm (e = 
1.3 [0.1%]). Purity was assessed by SDS-PAGE (Laemmli, 1970) and silver 
staining (Merril et al., 1984). When electrophoresed nonreduced, both pFN 
and cFN migrate primarily as dimers.  FNs were stored at -85"C in cyclo- 
hexylaminopropanesulfonic  acid (CAPS)-buffered  saline (0.15 M  NaCI, 
0.01 M CAPS, pH 11). For several control experiments, purified human or 
rat pFN was added to the culture medium of subconttuent F2408 Rat-1 cells 
at a final concentration of 10 $g/ml. Cells plus pFN were then incubated 
for an additional 2-3 d. Culture medium was collected and pFN and rat cFN 
were copurified  as described above. The yield of FN in the pFN  +  cFN 
preparation was twice that of cFN obtained from the same amount of culture 
medium. 
Cross-linking of FN in the absence of fibrin was assayed by incubating 
rat pFN or cFN separately on ice at 80/~g/ml in 0.15 M NaC1, 0.05 M Tris- 
HCI, pH 7.4, with 1 U/ml placental factor XIH, L5 U/nil bovine thrombin, 
20 m_M CaC12, and 0.5 mg human serum albumin/ml. Reactions were ter- 
minated by adding EGTA to 25 mM and PMSF to 2 mM. Components were 
solubilized  by addition of an equal volume of 8 M urea in CAPS-buffered 
saline. Approximately half of the total volume of each reaction was lyophi- 
lized in the SpeedVac (Savant Instruments, Farmingdale,  NY), reconstituted 
in 10/~1 water, electrophoresed  reduced, and immunoblotted with the VT1 
amibody. 
Purification of recFNs 
About  2  g  sterile  glass  microcarrier  beads  (ICN-Flow  Laboratories, 
McLean, VA) were seeded with cells trypsinized from four confluent 10-cm 
tissue culture dishes ("-'8 x  107 cells). Cells were allowed to attach 1 h to 
overnight in 100 ml DME plus 10% calf serum in a spinner flask (Techne, 
Inc., Princeton, NJ) at 37~  Medium volume was increased to 350 ml the 
next day. On day 6, the medium was aspirated and beads were washed with 
100 ml PBS supplemented with 0.9 raM CaC12 and 0.5 mM MgC12. The 
beads were then resuspended in 350 ml DME containing 10% calf serum 
depleted of bovine pFN by a 40% ammonium sulfate precipitation and/or 
gelatin-agarose affinity chromatography.  Cells were further incubated for 
7-10 d, at which time the conditioned medium was harvested, clarified by 
centrifugatiou, and applied to a gelatin-agarose column after the addition 
of EDTA to 10 mM and PMSF to 2 mM for protease inhibition. In some 
experiments, the medium was first incubated batchwise with gelatin beads, 
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were washed with PBS plus 1 mM EDTA; bound proteins were eluted with 
8 M urea in CAPS-buffered  saline. Fractions with the highest optical density 
at 280 nm were pooled and dialyzed into buffer. Several minor proteins were 
detected on silver-stained SDS-polyacrylamide gels of these pools and 
were the same in each preparation, recFN dimers were characterized by 
two-dimensional nonreduced/reduced SDS-PAGE as previously described 
(Schwarzbaner et al.,  1989). 
Separation and ldenfffication  of Cross-linked Products 
Proteins were separated on 5 %  SDS-polyacrylamide minigels ~io-Rad 
Laboratories, Cambridge, MA) unless indicated otherwise. For immuno- 
detection, proteins were transferred to nitrocellulose (Sartorius Corp., Bo- 
hemia, NY) using the transfer apparatus (Mini-Protean II; Bio-Rad Labora- 
tories) as suggested by the manufacturer. Filters blocked with 0.1% Tween 
20 in TBS were probed with either the VT1 mAb or an anti-haman FN mAb 
(clone lII; Telios Pharmaceuticals, Inc., San Diego, CA). The VT1 mAb 
was normally used as a 1:10 dilution of hybridoma culture supernatant for 
the detection of ,x,0.5/zg FN per lane with biotinylated goat anti-mouse IgG, 
streptavidin-horseradish peroxidase conjugate (both  from Gibco BRL, 
Gaithersburg, ME)), and 4CN. To visualize amounts <0.5/~g, or the recFNs, 
immunoblots were developed with chemiluminescent reagents (Amersham 
Corp., Arlington Heights, IL) and exposed to film (X-omat; Eastman Kodak 
Co., Rochester, NY). With this detection system, VTI culture supernatant 
was diluted 1:50 or 1:100; the anti-human FN m.Ab was used as a 1:10,000 
dilution of reconstituted ascites fluid. For the detection of human fibrin 
cross-linked products (6/~g fibrin per lane), affinity-purified mAbs against 
the a  and 3' subunits (Matsueda, G., Bristol Myers-Squibb Pharmaceutical 
Research Institute, Princeton, NJ) were used at  1:500  and 1:20,000  dilu- 
tions, respectively. For staining with Coomassie brilliant blue (0.25%  in 
50% methanol, 10% acetic acid), fibrinogan and FN concentrations in clot- 
ting reactions were increased to 3 mg/ml and 0.3 mg/ml, respectively, and 
aliquots of solubilized clots containing 30/~g fibrin and 3 ~g FN were elec- 
tropboresed. 
Quantitation  of Cross-linking 
Solubilized clots were electrophoresed on 4 or 4.5% gels and bands were 
detected on immunoblots with the chemiluminescence  system, using several 
exposure times. To determine the percentage of FN cross-linked at each 
time point, the amount of FN monomer remaining was measured using a 
technique developed by Suissa (1983).  In this method, bands are excised 
from the film and placed in 1 N NaOH to elute the silver grains. The absor- 
bance of  the silver grain solutions at visible wavelengths reflects the amount 
of protein in the band at appropriate exposure times. To ensure that the ab- 
sorbance was  indeed linearly  related to  the  amount  of protein,  bands 
representing 0.25 and 0.5/xg pFN on immunoblots were cut from film ex- 
posed to the filters for various times (between 5 and 60 s) and the silver 
grains were eluted. The absorbance of  the solutions was measured and plot- 
ted against time of exposure. The lines obtained for these two masses were 
linear and parallel, except for very rapid exposures (~5 s). Numbers calcu- 
lated using the silver grain elution method correlated well with those de- 
rived by densitometric scanning of appropriately blackened bands. 
We measured the amount of monomeric FN remaining in each reaction 
for silver grain suspensions with an absorbance between 0.45 and 0.05 at 
500 rim; measurements <0.05 are less reliable because of limitations in the 
sensitivity of  this method. Therefore, for light bands with an optical density 
<0.05, a combination of  exposures was used to determine  the amount of  pro- 
tein more accurately. These values were divided by that obtained for the 
noncross-linked  control and were then converted  to percent FN cross-linked 
and plotted as a function of time. For these experiments, time courses with 
the same or similar control absorbance values were compared. 
Results 
Clotting and Cross-linking Assay 
Formation of a blood clot is the culmination of a series of 
enzymatic reactions that result in the conversion of soluble 
fibrinogen, consisting of subunits Atx, B/3, and % to sponta- 
neously polymerizing fibrin molecules by thrombin-catalyzed 
cleavage of fibrinopeptides A  and B  (for review see Hen- 
schen and McDonagh, 1986).  Noncovalent binding of pFN 
to fibrin occurs via at least one domain on each subunit of 
the FN dimer (Hormann and Seidl, 1980;  Sekiguchi et al., 
1981;  see Fig.  2  A).  In the presence of Ca  2§  thrombin- 
activated factor XIII (Xffla) catalyzes formation of isopep- 
ride bonds between glutamine and lysine residues on fibrin 
7  and c~ subunits to generate 3' dimers and t~ polymers, 
respectively (Lorand, 1972). pFN is also cross-linked by this 
enzyme to lysine residues in the carboxy terminus of fibrin 
a chains (Iwanaga et al., 1978; Mosher and Johnson, 1983). 
The major factor XIIIa-reactive site in pFN has been mapped 
to a  glutamine at the amino terminus (McDonagh et al., 
1981;  Parameswaran et al.,  1990).  This fibrin-FN cross- 
linked network can be assembled from purified components 
in vitro using a clotting and cross-linking assay (Fig.  1 A) 
developed by Mosher (1975, 1976). In this assay, fibrin for- 
marion and polymerization (clotting) are rapidly initiated by 
the addition of thrombin to a solution of fibrinogen, factor 
XIII, FN,  and CaC12. Concomitantly, factor XIII is acti- 
vated and covalently cross-links fibrin and FN in a  Ca  2+- 
dependent reaction which is enhanced at low temperatures. 
At various times clots are solubilized with denaturing buffer. 
Cross-linked  products  are  then  separated  by  SDS-PAGE 
and analyzed either by Coomassie blue staining or immuno- 
blotting. 
Fig. 1 depicts the products of cross-linking of rat pFN to 
human fibrin at several time points. The Coomassie blue- 
stained gel (Fig. 1 B) shows the positions of  the three fibrino- 
gen subunits before clotting and cross-linking (lane/). Fibrin 
formation and cross-linking were induced in a  mixture of 
pFN and fibrinogen by the addition of thrombin and CaC12. 
After thrombin cleavage of the fibrinopeptides, the t~ and 
chains migrated ahead of their fibrinogen counterparts and 
the B and 3' chains comigrated (compare lanes 1 and 2). Fi- 
brin-cross-linked 3, dimers rapidly appeared, as well as sev- 
eral less intense u-polymer intermediates, as expected. With 
increased incubation times, the a  chains, which are cross- 
linked more slowly than 3, subunits (McKee et al.,  1970), 
were completely incorporated into high molecular weight 
polymers (asterisk, lane 4). In addition, pFN was converted 
into several cross-linked bands, particularly one migrating 
behind the monomer band (arrow). The composition of this 
band was determined by immunoblotting (Fig. 1 C). It was 
recognized both by a mAb to the human fibrin ot subunit and 
by a rat-specific anti-FN mAb, VT1 (arrow), and therefore 
represents a heterodimer of one pFN subunit (~250 kD) and 
a fibrin ct subunit (*65 kD). This pFN-fibrin t~ dimer is the 
major cross-linked intermediate at early time points. More 
complex polymers of FN and fibrin ~ chains were also visi- 
ble  with both  antibodies  (Fig.  1  C,  lanes 2  and 3)  and 
migrated as a heterogeneous smear. With extended incuba- 
tion (>18  h),  FN,  ot subunits,  and heterodimers were all 
completely converted into high molecular weight polymers 
seen at the top of the separating gel (Fig.  1 B, lane 4) and 
in the well (not shown). 
For these studies with rat FNs, we have primarily used a 
commercial  human  fibrinogen preparation  that  contains 
significant levels  of factor XIII activity and is efficiently 
cross-linked during the clotting reaction. Human fibrinogen 
has been completely sequenced and is probably the most 
thoroughly characterized fibrinogen to date (for review see 
Henschen and McDonagh,  1986).  Fibrinogen sequences, 
particularly  the  ot  chains,  are  somewhat  heterogeneous 
among vertebrate species (for reviews see Doolittle, 1973, 
1983);  for  example,  while  rat  and  human  fibrinogen 3" 
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The assay for clotting and cross-linking of purified 
fibrinngen and FN is outlined. (B) Clots were pre- 
pared with human fibrinogen and rat pFN at a mass 
ratio of 10:1. Clots wee solubilized under reducing 
conditions, electrophoresed in a 7 % SDS-polyacryl- 
amide  gel,  and  stained  with Coomassie  blue.  A 
short exposure of lane I shows the three subunits of 
fibrinogen  (Ate, BE,  and  3'). Thrombin  cleaves 
fibrinopeptides A and B, thus increasing the mobil- 
ity of the cr and/~ chains (compare lanes 1 and 2). 
At 30 (lane 2) and 60 min (lane 3) after thrombin 
addition,  Ca2+-dependent cross-linking  by  factor 
XIRa is evidenced by appearance of the  fibrin 3' 
dimer and concomitant conversion of fibrin c~ sub- 
units into higher molecular weight bands (~, and 
asterisk). FN is  incorporated  into  some of these 
polymers; the most distinct cross-linked intermedi- 
ate at 30 and 60 rain is an FN-fibrin c~ heterodimer 
(arrow) migrating behind the pFN monomer band. 
Note  the  complete  absence  of fibrin  c~ and  FN 
monomers at 18 h (lane 4), and the large polymers 
(asterisk) staining at the top of the separating gel. 
Not shown in this figure is staining of cross-linked 
material in the well. The fibrin/3 subunit does not 
participate  in  cross-linking.  (C)  Similar  60-rain 
clotting reactions were compared by immunoblot- 
ting with mAbs to the r  subunit of human fibrin 
(lanes 1 and 2) and to rat FN (lanes 3 and 4). Both 
antibodies  recognize  the  heterodimer  (arrow), 
which is not present if FN is omitted from the clotting reaction (lane 1). The other band recognized by the antifibrin antibody is a cross- 
linked ~ trimer. Other c~ polymers are not shown in this panel.  (Lane 1) -FN,  +Ca2+; (lanes 2 and 3)  +FN,  +Ca2+; (lane 4)  +FN, 
-Ca2+. 
subunits  are 83%  homologous, the As  chains show 64% 
identity (Crabtree and Kant,  1982; Crabtree et al.,  1985). 
On the other hand, all mammalian FNs are extremely well 
conserved (for review see Hynes, 1990). In fact, the amino 
acid  sequences  of the  amino-terminal  fibrin-binding  do- 
mains of human and rat FNs (type I repeats  1-5) are 96% 
identical. Furthermore, the amino-terminal type I repeats re- 
quired for cross-linking of recombinant rat FN fragments to 
human fibrin have been identified (Sottile et al.,  1991) and 
the alternatively spliced  structures of rat  FNs  have been 
more extensively characterized than in other species.  For 
these reasons, we elected to analyze the cross-linking of iso- 
forms of rat FN to human fibrin. 
Comparison of  pFN and cFN Covalent 
Incorporation into Clots 
The FNs are a  family of dimeric, modular proteins com- 
posed of repeating units, some of which confer binding to 
fibrin (Fig. 2 A). Rat plasma and cellular FNs share the same 
fibrin-binding  and  cross-linking  sequences  (Patel  et  al., 
1987), and Mosher has shown for human FN that each form 
is a substrate for the factor X[IIa-catalyzed addition of ly- 
sine analogues such as dansyl cadaverine (1975, 1976, 1977). 
Therefore, to determine if cFN,  like pFN,  can be cross- 
linked to fibrin, we compared the direct incorporation of the 
purified rat proteins into human and bovine fibrin clots and 
clots formed from rat plasma using a rat-specific mAb (Fig. 
2 B). cFN was incorporated into these clots, but, in compar- 
ison to pFN, there was a striking difference in the extent of 
cross-linking to fibrin. While the majority of pFN was con- 
verted into the FN-fibrin ot heterodimer by the first time 
point,  cFN was  only partially cross-linked.  In  fact, cFN 
subunits  could  still  be  detected  in  clotting  reactions  in- 
cubated >18 h, whereas all pFN subunits, and most of the 
pFN-fibrin a heterodimers, were converted into high molec- 
ular weight polymers. The incorporation of FNs was slower 
with bovine than with human fibrinogen or rat plasma. Com- 
paratively lower amounts of bovine fibrin 3' dimers were de- 
tected on Coomassie blue-stained gels at early time points, 
indicating that  the difference was  most likely due to  the 
amount or activity of factor XIR copurifying with bovine 
fibrinogen. Addition of purified placental transglntaminase 
to fibrinogens with lower indigenous factor XRI activity than 
that  of human  fibrinogen did  increase  the  rate  of cross- 
linking, but the difference between the extent of incorpora- 
tion  of pFN  and  cFN  was  still  observed for  these  sup- 
plemented reactions (data not shown). A similar difference 
between pFN and cFN was found with purified rat fibrinogen 
(data not shown);  however, the rat fibrinogen preparation 
was not used further since these fibrin clots contained very 
little active factor XIII. 
The major structural differences between pFN and cFN 
are generated by tissue-specific alternative splicing (Schwarz- 
bauer et al.,  1985; Paul et al.,  1986) and could explain the 
cross-linking differences. Two other explanations for these 
results, differential glycosylation and solubility, were elimi- 
nated by the following control experiments. In both mole- 
cules, the major carbohydrate group is the biantennary com- 
plex asparagine-linked side chain.  Unlike pFN,  cFN side 
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pFN and cFN. (A) This schematic of an FN subunit depicts the do- 
mains for binding to fbrin and collagen (gelatin),  as well as the 
amino-terminal  factor XIIIa-reactive site. The domains are com- 
posed of three typos of repeating units: type I (boxes), type II (tri- 
angles), and type III (ovals).  EIIIA  and EIIIB are cFN-specific type 
III repeats. Almost all Rata cFN subunits in these experiments are 
V  +, whereas this region is completely excluded (I10) in ~40% of 
rat pFN subunits. Subunits are disulfide bonded into dimers via a 
pair of cysteines at the carboxy terminus (SS). Below this subunit 
is a diagram of  the cDNA-encoded recFN used in the clotting assay. 
This 180-kD recFN lacks repeats III~_7,  EIIIA, and EIIIB, and ei- 
ther includes or excludes (I49) the V region. This recFN was used 
for these  experiments  because  we have been unable  to produce 
sufficient quantities of full-length recFN by expressing cDNAs in 
mouse fibroblasts.  (B) Equal  masses  of rat pFN and cFN were 
added  to  clotting  reactions  containing  either  human  or bovine 
fibrinogen or rat plasma depleted of endogenous FN. Immunoblots 
of reactions terminated at the given time points were probed with 
the  VT1  mAb.  (Lanes  1 and  4)  -Ca  2+, >18  h;  (lanes 2  and 5) 
+Ca  2+, 2 h; (lanes 3 and 6)  +Ca  2+, >18 h. Arrowheads  indicate 
FN-fibrin tx heterodimer, pFN migrates as a doublet corresponding 
to V  § and V0 subunits,  whereas  monomeric cFN migrates  as a 
diffuse band. 
chains have been reported to contain fucose, and compara- 
tively  less  sialic  acid  (Vuento  et  al.,  1977;  Carter  and 
Hakomori,  1979).  To discern if carbohydrate organization 
has any role in the interaction of FN with fibrin during clot- 
ting, we metabolically labeled Rat-1  fibroblasts in the pres- 
ence of tunicamycin to inhibit asparagine-linked glycosyla- 
tion,  purified  cFN  from  the  conditioned  medium,  and 
analyzed its incorporation into clots. Because there was no 
difference in the rate of cross-linking when compared with 
native  cFN,  asparagine-linked  carbohydrate  groups  must 
have no effect on the incorporation of FN into fibrin clots 
(data not shown). 
The two forms also reportedly differ in solubility (Hynes, 
1990). During clotting, nonspecific aggregation of cFN mol- 
ecules could decrease accessibility of the protein to factor 
XIIIa, thereby reducing the rate at which cFN is incorpo- 
rated. Accordingly, the solubilities of pFN and cFN were ex- 
amined by incubating  them at neutral pH with CaC12 and 
either BSA or factor XIII-depleted fibrinogen. The mixtures 
were centrifuged at various time points to pellet any protein 
aggregates. A sample of each supernatant was removed and 
compared with  controls.  Because  the  band  intensities  for 
pFN and cFN were the same as the controls, we conclude 
that both FN forms remained soluble under these conditions 
(data not shown). 
Time Course of Incorporation 
To monitor the progression of cross-linking early after fibrin 
clot  formation,  we assayed the  incorporation of pFN and 
cFN into fibrin gels using a wider range of time points (Fig. 
3 A). This time course shows the same kinetic differences in 
cross-linking of the FNs, but also emphasizes a difference in 
the  nature  of the  cross-linked  products  obtained.  Cross- 
linking of pFN to fibrin tx subunits  was clearly visible as 
early  as  5  min  after  the  addition  of  thrombin,  while 
cFN-fibrin cross-linked products appeared at significantly 
later times. While the FN-fibrin tx heterodimer (arrow) was 
a  major intermediate in pFN-fibrin clots,  this was not the 
case for fibrin gels containing cFN. Instead, the incorpora- 
tion of cFN was characterized primarily by the production 
of high molecular weight polymers (asterisks).  In a parallel 
experiment, the extent of cross-linking was quantitated by 
measuring the percentage of monomeric FN  remaining at 
each time point (Fig. 3 B). By 45 min, pFN was essentially 
completely incorporated into the clot, whereas only 40--45 % 
of cFN subunits were cross-linked. Although cFN continued 
to be gradually cross-linked, it was not entirely incorporated 
even after 24 h. The graph also shows values at several early 
time points for reactions carded out at 37~  Plots of these 
values closely follow those of reactions performed on ice, in- 
dicating these differences persist under variable conditions. 
The pFN and cFN preparations used in these experiments 
were purified  by  gelatin-agarose affinity  chromatography 
from two different sources,  fresh blood plasma and fibro- 
blast-conditioned medium, respectively. Since no difference 
in fibrin-fibrin cross-linking between clots containing pFN 
or cFN could be detected, it appears that thrombin activation 
of factor XIII proceeds at the same rate (data not shown). 
To determine if there were elements from conditioned me- 
dium that were copurifying with cFN and affecting its cross- 
linking to fibrin,  several control experiments were carried 
out. Human pFN and rat cFN were mixed together in clot- 
ting reactions. Solubilized clots were immunoblotted with a 
mAb against human FN and compared with reactions con- 
taining pFN alone (data not shown). In a second mixing ex- 
periment,  human pFN purified from outdated plasma was 
added to rat fibroblast cultures and incubated for 2 d. Human 
pFN was then isolated from the culture medium along with 
rat cFN and compared to nonincubated pFN in the clotting 
assay (Fig.  4  A).  In both types of mixing experiment,  the 
rates and patterns of cross-linking of human pFN to fibrin 
were similar in the presence and absence of rat cFN, show- 
Wilson and Schwarzbauer  Cross-linking of Fibronectins into Fibrin Clots  927 Figure 3. Time course of incorporation of rat pFN and cFN into human fibrin clots. (A) Clotting reactions were terminated at the indicated 
time points and analyzed by immunoblotting with the VT1 mAb. The dash denotes the noncross-linked control. Stacking gels were retained 
to show high molecular weight material migrating at the top of the separating gels and in the wells at later time points (asterisks). Arrows 
indicate FN-fibrin ot heterodimer. (B) The rate of cross-linking of pFN (o, 0~  zx, 37~  and cFN (o, 0~  A, 37oC) was quantitated 
at various time points as described in Materials and Methods. 
ing that contaminating components of the fibroblast culture 
medium are not responsible for the differences between pFN 
and cFN. 
In  a  more direct control experiment,  rat pFN  was  in- 
cubated with rat fibroblasts and the mixture of rat pFN  + 
cFN was copurified from the culture medium. Cross-linking 
of the  mixture was  compared with  cross-linking  of cFN 
purified from a parallel culture. Although the VT1 antibody 
recognizes both pFN and cFN equally well, cross-linking of 
the two forms could be distinguished by monitoring the lev- 
els of the FN-fibrin c~ heterodimer, which is a major inter- 
mediate in pFN-fibrin reactions. In the pFN +  cFN clotting 
reactions (Fig. 4 B, top), this cross-linked intermediate had 
the doublet appearance characteristic of pFN and was evi- 
dent well before any cross-linking of  cFN had occurred (Fig. 
4 B, bottom). Furthermore, a direct comparison of the two 
sets  of  reactions  clearly  shows  the  pFN-specific  cross- 
linking above the cFN background. Significant differences in 
the amounts of high molecular weight cross-linked products 
were also  observed after overnight incubations  (compare 
Fig. 4 B, lanes 5). Together, the results of these control ex- 
periments indicate that the difference in the rate of cross- 
linking of  the two forms must be inherent in the FN molecule 
itself. 
Formation of cFN-cFN Cross-linked Intermediates 
A comparatively slow rate of cross-linking, in conjunction 
with reduced formation of cFN-fibrin c~ heterodimers, sug- 
gests that the mechanism of cFN incorporation into fibrin 
clots differs from that of pFN. We hypothesized that if cFN 
dimers could self-associate and were cross-linked to each 
other by factor XIIIa, this interaction might alter binding and 
cross-linking of cFN to fibrin. In fact, when incubated with 
CaC12 and placental factor XIIIa,  a  small fraction of cFN 
molecules was  cross-linked into FN-FN dimers and con- 
jugates migrating at the top of the separating gel'(Fig. 5, ar- 
rowheads). As expected, the cross-linked dimers comigrated 
with purified dimeric cFN (data not shown). Cross-linking 
of pFN molecules to each other was  not detected in this 
experiment (Fig.  5),  in  agreement with  Mosher's  results 
(1975). Homotypic interactions and/or cross-linking of cFN 
during clot formation could result in reduced efficiency  of in- 
corporation into  the  clot and  decreased  incidence of the 
cFN-fibrin ot heterodimer on gels. Indeed, it is possible that 
polymers of  cross-linked cFN, rather than native dimers, are 
involved in the interaction with fibrin. The time course of 
cFN incorporation shown in Fig. 3 A reveals at least one ad- 
ditional cross-linked intermediate in the 5-h reaction that 
was not present in fibrin-pFN clots. 
Characterization of  Recombinant V+-VO 
and V+-V  § Dimers 
Differential incorporation of pFN and cFN appears to be due 
to structural differences between the two forms. Alternative 
splicing of the V region is one feature that distinguishes pFN 
from cFN dimers. Since native FNs are a population of splic- 
ing variants, we needed an approach that would allow analy- 
sis of these regions independently of each other. Therefore, 
SVT2 cells were engineered to produce recFN dimers vary- 
ing only in the number of V  segments per dimer, as illus- 
trated in Fig. 6 A. Compared with a native FN subunit (Fig. 
2 A), the recombinant versions lack the first seven type III 
repeats, as well as the alternatively spliced segments EIIIA 
and EHIB,  and  either contain  (recV  +)  or lack  (recVO) the 
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incubated separately in clotting buffer plus thrombin and placental 
factor XIII but with serum albumin in place of fibrinogen. Reac- 
tions were terminated at the times indicated and components were 
solubilized and immunoblotted with the VT1 mAb. (Lanes 1)  15 
min; (lanes 2) 1 h; (lanes 3) 23-24 h. Arrowheads indicate cross- 
linked products. 
was infected with a second retrovirus carrying sequences en- 
coding recV0 and a different selectable marker, hisD (Hart- 
man and Mulligan, 1988). Cells able to grow in the presence 
of G418 and histidinol were screened for secretion of recV  § 
and recV0 polypeptides, recFNs from one clone expressing 
Figure 4. Cross-linking  ofpFN after incubation with rat fibroblasts. 
(A) Human pFN was purified from outdated plasma and used in the 
clotting assay without further manipulations (top) or after incuba- 
tion with rat fibroblast  cultures (bottom).  Equal amounts of human 
pFN were used in the two sets of reactions. Reactions were ter- 
minated at various times after thrombin addition: (lane 1)  -Ca  2+ 
control; (lane 2)  +Ca  2+, 30 min; (lane 3) 1 h; (lane 4) 2 h; (lane 
5) 20 h. Aliquots containing 0.25 #g human pFN from each clot 
were immunoblotted with an anti-FN mAb recognizing only the hu- 
man form and detected using chemiluminescence. Arrows indicate 
FN-fibrin c~ heterodimer. (B) Purified rat pFN was added to rat 
fibroblast  cultures and incubated for several days. Rat pFN and eFN 
were copurified and eFN alone was purified from a parallel culture. 
Fibrin clots were prepared using either the rat pFN +  cFN mixture 
(top) or rat cFN alone (bottom) with equal quantities ofcFN in each 
reaction. Cross-linked products were detected with the rat-specific 
VT1 antibody. Times after thrombin addition (lanes 1-5) are as in 
A.  Arrows indicate FN-fibrin a  heterodimer.  The pFN  +  eFN 
panel is a  shorter exposure than the cFN alone to provide better 
visibility of individual bands. 
entire  V  segment.  Details of the  eDNA  construction  and 
characterization  of recV  §  have  been  previously described 
(It-9/Cll0; Sehwarzbauer,  I991).  To generate recombinant 
V§  dimers, the G418-resistant cell line producing recV  + 
Figure 6. Analysis of recombinant FN dimers. (A) The recFN di- 
mers engineered for these studies, V+-V  + by expression of a single 
eDNA, V+-V0 by eoexpression of two eDNAs. The major recFN 
dimers secreted by the SVT2 cell lines are illustrated here. With re- 
gard  to  V-region splicing pattern,  V+-V  + dimers  are like cFN, 
whereas V+-V0 dimers resemble pFN. The domain structure of the 
nearly full-length recombinant subunits comprising these dimers is 
diagrammed in Fig. 2 A. The X denotes the amino-terminal factor 
XIIIa-reactive site.  (B)  The  fluorogram  shows  FNs  immuno- 
precipitated with a polyclonal anti-FN Ab from the parental recV  + 
(lane 1)  and the recV+-recV0-secreting SVT2 clone resistant to 
G418 and histidinol (lane 2). The position of the recombinant sub- 
units relative to endogenous eFN is indicated. The molar ratios of 
recV  + and  recV0  to  endogenous eFN  were  3.3  and  5.0, respec- 
tively. In the double infectant, there is a band of unknown origin 
migrating ahead of reeV0 that is recognized by the VT1 mAb. Less 
protein was loaded in lane 1 than lane 2. 
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reduced  SDS-PAGE of  recFN  dimers. 
FNs  were  isolated  by  gelatin-agarose 
affinity  chromatography  after  labeling 
cells with  [35S]methionine for 24 h.  Di- 
mers  were  separated  without  reduction 
(left to right), reduced in situ, and electro- 
phoresed in the second dimension (top to 
bottom).  These  fluorograms  show the 
composition of  dimers secreted from cells 
producing recV  + subunits singly (left) or 
simultaneously with recV0  (right). In each 
panel, the arrows point to the recombinant 
dimers and the arrowheads indicate recFN-cFN heterodimers.  The recV0 monomer is denoted by the open arrow. The positions of the 
subunits were verified by electrophoresing  the same samples reduced only (not shown). In both cases, very few cFN homodimers  are 
secreted.  In the parental  recV  + cell line,  we calculate that no more than 35 % of this recFN dimerizes with endogenous cFN. 
both recV  § and recV0  (recV+-recV0)  are compared with the 
parent recV  § in Fig.  6 B. 
Because  the  recombinant  subunits  were made  in  SVT2 
fibroblasts, which synthesize their own FN, albeit at low lev- 
els, a  relatively complex array of dimers was possible.  To 
characterize the  composition of dimers  secreted by these 
cells, two-dimensional nonreduced/reduced SDS-PAGE was 
performed. Samples were first electrophoresed nonreduced 
in SDS-polyacrylamide tube gels, then reduced in situ, elec- 
trophoresed  in  the  second  dimension,  and  processed  for 
fluorography.  Fig.  7  displays the  two-dimensional profiles 
obtained  for  both  cell  lines.  From  the  recV§ 
clone, the majority of recombinant subunits were dimerized 
with each other (arrow,  left)  as previously shown on non- 
reduced  one-dimensional  gels  (Schwarzbauer,  1991).  On 
the  other hand,  the  recV+-V0-producing clone synthesizes 
recV0 subunits at higher levels than recV§  therefore,  these 
subunits were secreted in three forms (right):  as a heterodi- 
mer with endogenous FN (cFN-recV0, arrowhead), as a het- 
erodimer with all the recV  + subunits (recV+-V0, arrow), and 
the majority as a monomer (open arrow),  recV0-V0 dimers 
were not detected, as expected (Schwarzbauer et al.,  1989), 
nor were recV+-V  § dimers. Thus, because virtually all cFN 
subunits are V §  all dimers in the conditioned medium from 
the recV+-producing clone are V§  + and resemble cFN. In 
contrast,  the  dimers  secreted  by  the  recV+-V0 cell  line, 
which  include  cFN-recV0 and recV+-V0, contain the V  re- 
gion in only one subunit and are like pFN. 
For the  large-scale production  of recombinant polypep- 
tides,  cells  were grown  on  microcarrier beads  in  spinner 
flasks. The conditioned medium was harvested and subjected 
to gelatin-agarose affinity chromatography. This procedure 
resulted in purification of both endogenous cFN and recFNs. 
Cross-linking of recFN Subunits to Fibrin 
Using the  clotting assay,  we compared the rates of incor- 
poration  of purified  recV§  and  recV+-V  + dimers.  After 
solubilization, cross-linked products were analyzed by SDS- 
PAGE and immunoblotting with the VT1 mAb, which detects 
only the recFNs. The time course in Fig. 8 A shows that these 
recV  § and recV0  FN polypeptides were competent for fac- 
tor XIIIa-mediated incorporation  into  fibrin clots.  Cross- 
linking was evidenced by Ca2+-dependent disappearance of 
monomer bands and formation of new products,  including 
prominent intermediates (arrows) and high molecular weight 
complexes.  These  cross-linked products  were also  recog- 
nized by the mAb against the fibrin o~ chain (data not shown). 
The  recV+-V  § dimers  were  cross-linked  relatively  slowly, 
with some noncross-linked recV  § remaining after overnight 
incubation (Fig. 8 A, bottom). In comparison, immunoblots 
of clots  formed with  recV0-containing  FNs  showed  more 
complex  patterns  due  to  the  existence  of multiple  recV0 
forms  (recV+-V0,  cFN-recV0,  recV0  monomer).  We  were 
primarily  interested  in  monitoring  the  fate  of the  recV  § 
subunits in these reactions, since these subunits were always 
present  as  recV+-V0 dimers  (Fig.  7).  Cross-linked  inter- 
mediates of both recV  § and recV0 proteins with fibrin were 
formed early  in  the  time course  and  the  majority of the 
recV  §  subunits  was  cross-linked  by  2  h  (Fig.  8  A,  top). 
Quantitation of the recV  § band in each time course showed 
that it was not incorporated at the same rate (Fig.  8 B). As 
a  heterodimer with  recV0,  83 %  of recV  § was cross-linked 
into the fibrin clot by 1 h. In contrast, when paired with an- 
other V § subunit,  only 35 % was incorporated at this time 
point  and,  as  observed  for  cFN,  recV+-V  § was  not  com- 
pletely cross-linked over the 24-h time period. 
To demonstrate that the factor XIIIa activity was equiva- 
lent in both sets of reactions, rat pFN was mixed with recFN 
preparations and monitored for its incorporation into clots. 
The pattern of pFN-fibrin cross-linking was identical when 
mixed with preparations containing recombinant proteins or 
analyzed by itself (data not shown). This experiment elimi- 
nated the possibility of a contaminant specific to one of the 
preparations as a  factor in the differential incorporation of 
the recFNs. In fact, in multiple experiments, we consistently 
observed  an  accelerated  rate  of  recV§  cross-linking. 
Data from several experiments showing the difference be- 
tween  percent  recV  §  cross-linked  at  two  time  points  are 
presented in Table I. Although the 30-min values were more 
variable,  the  differences between cross-linking of the  two 
kinds of recombinant dimers were almost 50% at the 1-h time 
points. 
Discussion 
Cross-linking of pFN to fibrin within the blood clot matrix 
is required for cell adhesion and migration (Grinnell et al., 
1980; Knox et al.,  1986). In vivo, recruitment of some cell 
types (neutrophils, monocytes, epidermal cells, fibroblasts) 
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and recV+-V  + Dimers 
Difference  in % cross-linked 
Experiment  30 min  60 rain 
1  25.8  46.2 
2  37.2  48.2 
3  23.5  47.6 
FNs derived from the recV +- and recV+-VO-producing  cells were clotted with 
human fibrinogen for the indicated  times in three independent experiments. Im- 
munoblots  probed with the VT1  mAb were developed and bands quantitated 
as described in Materials and Methods.  Difference in % cross-linked =  differ- 
ence between recV+-VO and recV+-V  + values at the indicated time points. 
Figure 8.  Time  course  of incorporation  of recV  + subunits  into 
clots. (A) FN polypeptides were purified by gelatin-agarose  chro- 
matography  from the conditioned  medium of the two SVT2 cell 
lines. Proteins were added to clotting reactions containing human 
fibrinogen. Clots were solubilized and rat-specific proteins detected 
by immunoblotting with the VTI mAb to follow the cross-linking 
of recV+-V0 dimers (top) and recV+-V  + (bottom). Blots were devel- 
oped using the chemiluminescence system. The recV0 band is more 
intense than the recV  + since its expression level is higher, but most 
of it is present  as a monomer.  The ~s  point to cross-linked 
recFN-fibrin tx intermediates-a single recV+-fibrin ct band (bot- 
tom), as well as both recV+-fibrin tx and recV0-fibrin ct bands (top, 
bracket).  (B) Bands representing  recV  + (o, in V+-V0 dimers;  o, 
in V+-V  + dimers) were excised from films exposed to the blots in 
A and  processed  for quantitation  as described  in Materials  and 
Methods. 
into the wound area begins very early after clot deposition; 
therefore timely  incorporation  of FN  into  the  clot  would 
benefit those cells that are dependent  on its presence in a 
provisional matrix (Grinnell  et al.,  1981;  Fujikawa et al., 
1981;  Clark et al,,  1982;  Lanir et al.,  1988).  The experi- 
ments reported here show that compared with pFN,  cross- 
linking of cFN to fibrin by factor XIIIa is less efficient. In 
the comparison presented in Fig. 3, the majority ofpFN was 
cross-linked to human fibrin within 30 min, while <50 % of 
cFN was cross-linked at this time. A difference in the cross- 
linking of the two FNs was maintained with fibrins from hu- 
man,  bovine,  and  rat  and  in  the  context  of FN-depleted 
whole blood plasma. In addition,  differential incorporation 
was observed at 37~  and 0~  the latter a temperature that 
favors fibrin-FN interactions. 
Along with differences in rate of cross-linking, cFN incor- 
poration into fibrin clots proceeds through a more complex 
spectrum of cross-linked intermediates.  The  major inter- 
mediate in pFN-fibrin reactions  is  a  heterodimer of pFN 
cross-linked to the ot subunit of fibrin. With time, this hetero- 
dimer is converted into high molecular weight cross-linked 
polymers. Compared to pFN,  much lower levels of cFN- 
fibrin c~ heterodimer  are  formed,  both at 0~  and  37~ 
Instead,  cFN  is  apparently  incorporated  directly  into  the 
large polymers. This could be merely a consequence of the 
delay in cross-linking to fibrin, such that when cFN is finally 
incorporated, significant cross-linking has already occurred 
between the ot chains,  and therefore complexes larger than 
the heterodimer are formed. Another possibility is that cFN 
preferentially  interacts  with  a  network  of cross-linked  ot 
polymers rather than  single subunits.  Okada et al.  (1985) 
found that pFN does not become cross-linked to fibrin until 
the  gel  point  and  proposed  that  some  form  of  three- 
dimensional structure is necessary for the reaction. Invoking 
their model, it may be that cFN has a more stringent require- 
ment for cross-linked multimeric ot chains than pFN. 
That cFN can serve as both donor and acceptor in factor 
Xl/Ia-catalyzed reactions might also explain the low level of 
cFN-fibrin ot heterodimer. A cFN-cFN cross-linked dimer 
was detected as early as 15 min after the addition of thrombin 
to a solution containing purified cFN, placental factor XIII, 
and  CaC12. Under our experimental conditions,  this reac- 
tion was not extensive, which may be a consequence of either 
the activity of the factor XIII  preparation or the accessibility 
of appropriate glutamines and lysines. However, our results 
show that cFN molecules interact with each other differently 
from pFN. It is possible that cFN-cFN cross-linking occurs 
during clot formation as well. In fact, one of the intermedi- 
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pected for a cFN-cFN-fibrin a  complex. Interactions be- 
tween cFN molecules could prevent fibrin binding and result 
in a slower rate of incorporation into the clot. Three domains 
for noncovalent binding of FN to fibrin have been identified: 
the major amino-terminal binding domain, the weaker car- 
boxy-terminal region (Sekiguchi et al.,  1981; Hayashi and 
Yamada,  1983),  and a third region spanning the last type I 
repeat of the gelatin-binding domain and at least the first type 
III repeat (Seidl and Hormann, t,983). Interestingly, each of 
these sites has also been implicated in FN-FN interactions 
(Ehrismann et al., 1981; Homandberg and Erickson, 1986; 
Chernousov et al.,  1991; Schwarzbauer,  1991; Morla and 
Ruoslahti, 1991). 
The major structural differences between cFN and pFN 
are due to the presence or absence of alternatively spliced 
segments, pFN has a  relatively simple dimer structure in 
which one subunit contains the V region and the other lacks 
this segment, cFN is composed of  a more complex repertoire 
of subunits with variation at three sites-EIIIA, EIIIB, and 
the  V  region.  Because  the  V  region is  present  in  both 
subunits of cFN dimers but in only one subunit of the pFN 
dimer,  we speculated that this segment might have some 
effect on the cross-linking of cFN during clot formation, de- 
spite its distance from the amino-terminal factor XIIIa-reac- 
tive site.  To analyze the effects of this segment apart from 
other variations in the protein, the V region splicing patterns 
of pFN and cFN were recapitulated in recombinant V§ 
and V§  + dimers, respectively. Aside from the inclusion or 
exclusion of the  120-amino  acid V  region, these recom- 
binant polypeptides were identical. Because the V region is 
required  for  FN  dimer  secretion  (Schwarzbauer  et  al., 
1989), recV0 homodimers are not secreted and could not be 
tested. 
When recFN polypeptides were tested in the clotting as- 
say, we found that the context in which recV  § was presented 
markedly  influenced  its  rate  of  cross-linking  to  fibrin. 
recV  § cross-linking as a  dimer with recVO was similar to 
that of pFN.  Furthermore, endogenous cFN (V  §  subunits 
were also cross-linked more rapidly When paired with recV0 
(Wilson, C. L., and J. E. Schwarzbauer, unpublished obser- 
vations), recV  + homodimers, on the other hand, were cross- 
linked more slowly, reminiscent of  cFN-fibrin cross-linking. 
Although the rates of incorporation differed, we did not ob- 
serve a consistent variation in the types of intermediates as 
we had with pFN and cFN. Taken together, these findings 
implicate the V region of FN as a factor in determining the 
efficiency of incorporation into fibrin clots. 
How does a region downstream of the amino-terminal fac- 
tor XIIIa-reactive site exert an effect on this kind of  reaction? 
One possibility is that the V  segment alters the folding of 
subunits to modify interactions with fibrin via the adjacent 
carboxy-terminal fibrin-binding domain. The extent of fibrin 
binding by fragments containing this domain can vary de- 
pending on the buffer conditions used and the molecular con- 
text (Sekiguchi et al.,  1981; Hayashi and Yamada,  1983). 
Fragments from the carboxy terminus of the B (V0) subunit 
of pFN appeared to interact more weakly with fibrin-Seph- 
arose than  fragments from the A  (V  §  chain,  suggesting 
that the V region can modulate fibrin-FN interactions. Simi- 
larly, the juxtaposition of two carboxy-terminal fibrin do- 
mains in a disulfide-bonded FN dimer could have an effect 
on fibrin binding. In any case, interactions between the car- 
boxy-terminal region and fibrin would probably put con- 
straints on binding and cross-linking at the amino-terminal 
site. Perhaps the absence of the V region in one of the sub- 
units is sufficient to allow binding at the amino terminus to 
predominate. 
It is also possible that the V region contributes residues 
involved in cross-linking by factor XIIIa.  Several groups 
have demonstrated the existence of factor XIIIa-reactive 
sites near the carboxy terminus of FN using radiolabeled ly- 
sine analogues (Jilek and Hormann,  1977; Richter et al., 
1981; Williams et al.,  1982;  Molnar et al.,  1983;  Fesus et 
al.,  1986).  There is a conserved glycine-glutamine-gluta- 
mine sequence in the V segments of human, bovine, rat, and 
chicken FNs and this tripeptide sequence is analogous to the 
amino-terminal factor XIIIa-reactive site. V region partici- 
pation in transglutaminase-mediated cross-linking to itself 
or to fibrin would further affect interactions via the primary 
site at the amino terminus. 
The difference in the rate and pattern of cross-linking of 
pFN and cFN during clotting demonstrates that these forms 
have temporally and structurally specific roles in the tissue 
repair process. An asymmetric distribution of the V segment 
in blood FN is important for its specific role in the coagula- 
tion  pathway,  whereas  the  V+-V  §  forms  comprising  the 
majority of FNs in vivo are specialized for assembly into in- 
soluble fibrils in the extracellular matrix. The alternatively 
spliced EIIIA and EIIIB segments, which are absent in pFN 
but predominate in newly synthesized cFN in the wound 
(ffrench-Constant et al., 1989),  may also play some role in 
modulating the interactions and functions of cFN. Involve- 
ment of alternatively spliced regions in the different phases 
of blood clotting and tissue repair would provide a satisfying 
explanation for the evolution of the splicing patterns of pFN 
and cFN. The experiments described here provide a founda- 
tion  for  further work  to  define the  importance  of other 
regions in the differential cross-linking ofpFN and cFN, and 
to determine the role of these segments in cell adhesion and 
migration on fibrin clots. 
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